SG159542A1 - Compositions against sars-coronavirus and uses thereof - Google Patents
Compositions against sars-coronavirus and uses thereofInfo
- Publication number
- SG159542A1 SG159542A1 SG201000925-6A SG2010009256A SG159542A1 SG 159542 A1 SG159542 A1 SG 159542A1 SG 2010009256 A SG2010009256 A SG 2010009256A SG 159542 A1 SG159542 A1 SG 159542A1
- Authority
- SG
- Singapore
- Prior art keywords
- coronavirus
- compositions against
- sars
- against sars
- compositions
- Prior art date
Links
- 241000315672 SARS coronavirus Species 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 241000711573 Coronaviridae Species 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62777304P | 2004-11-11 | 2004-11-11 | |
EP04105684 | 2004-11-11 | ||
EP04106192 | 2004-11-30 | ||
EP05102117 | 2005-03-17 | ||
EP05107288 | 2005-08-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG159542A1 true SG159542A1 (en) | 2010-03-30 |
Family
ID=35747767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG201000925-6A SG159542A1 (en) | 2004-11-11 | 2005-11-10 | Compositions against sars-coronavirus and uses thereof |
Country Status (9)
Country | Link |
---|---|
US (1) | US8106170B2 (de) |
EP (1) | EP1812067B1 (de) |
KR (1) | KR101255861B1 (de) |
AT (1) | ATE550037T1 (de) |
AU (1) | AU2005303758B2 (de) |
CA (1) | CA2582057C (de) |
NZ (1) | NZ553701A (de) |
SG (1) | SG159542A1 (de) |
WO (1) | WO2006051091A1 (de) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2314629B2 (de) | 2002-07-18 | 2022-11-16 | Merus N.V. | Rekombinante Herstellung von Mischungen aus Aantikörpern |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
EP1573012B1 (de) | 2002-12-17 | 2011-11-30 | Crucell Holland B.V. | Rekombinanter virus-basierter malaria impfstoff |
CA2527694C (en) | 2003-05-30 | 2015-07-14 | Hendricus Renerus Jacobus Mattheus Hoogenboom | Fab library for the preparation of anti vegf and anti rabies virus fabs |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
AU2004260884B2 (en) * | 2003-07-22 | 2009-11-19 | Crucell Holland B.V. | Binding molecules against SARS-coronavirus and uses thereof |
AU2005250163B2 (en) | 2004-05-27 | 2011-08-25 | Crucell Holland B.V. | Binding molecules capable of neutralizing rabies virus and uses thereof |
AU2005293560B2 (en) * | 2004-10-12 | 2011-10-06 | Crucell Holland B.V. | Binding molecules for treatment and detection of cancer |
SI1802336T1 (sl) * | 2004-10-14 | 2012-01-31 | Crucell Holland Bv | Začetna/obnovitvena cepiva proti malariji |
WO2006120230A2 (en) | 2005-05-12 | 2006-11-16 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
WO2007044695A2 (en) * | 2005-10-07 | 2007-04-19 | Dana-Farber Cancer Institute | ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF |
WO2008060331A2 (en) * | 2006-05-19 | 2008-05-22 | Amgen Inc. | Antibodies to sars coronavirus |
KR101508390B1 (ko) | 2006-06-06 | 2015-04-08 | 크루셀 홀란드 비.브이. | 포도상구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도 |
KR101485197B1 (ko) | 2006-09-07 | 2015-01-23 | 크루셀 홀란드 비.브이. | 인플루엔자 바이러스 h5n1을 중화시킬 수 있는 인간 결합분자 및 그것의 용도 |
CN102015767A (zh) * | 2008-01-17 | 2011-04-13 | 胡马斯有限公司 | 针对SARS-CoV的交叉中和人单克隆抗体及其使用方法 |
BRPI0910206A2 (pt) | 2008-06-30 | 2015-09-29 | Koninkl Philips Electronics Nv | sistema de formação de imagem de tomografia computadorizada e método |
WO2011124635A1 (en) * | 2010-04-07 | 2011-10-13 | Humalys | Binding molecules against chikungunya virus and uses thereof |
EP2374816B1 (de) * | 2010-04-07 | 2016-09-28 | Agency For Science, Technology And Research | Bindemoleküle gegen Chikungunya-Virus und Verwendungen davon |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
JP6393255B2 (ja) | 2012-04-20 | 2018-09-19 | メルス ナムローゼ フェンノートシャップ | ヘテロ二量体のIgG様分子を生産する方法、ヘテロ二量体のIgG様分子、ヘテロ二量体の抗体、組み換え宿主細胞、医薬組成物、宿主細胞を作成する方法、および培養物 |
ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
BR112016030183A2 (pt) | 2014-06-26 | 2017-11-14 | Janssen Vaccines & Prevention Bv | anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos |
WO2021148884A1 (en) * | 2020-01-24 | 2021-07-29 | Tychan Pte. Ltd. | Anti-wuhan coronavirus antibodies |
WO2021156490A2 (en) | 2020-02-06 | 2021-08-12 | Vib Vzw | Corona virus binders |
CA3158752C (en) | 2020-02-26 | 2023-08-08 | Davide Corti | Antibodies against sars-cov-2 and methods of using the same |
US20210292393A1 (en) | 2020-03-09 | 2021-09-23 | Abcellera Biologics Inc. | Anti-Coronavirus Antibodies and Methods of Use |
WO2021201679A1 (en) | 2020-04-01 | 2021-10-07 | Kiadis Pharma Intellectual Property B.V. | Compositions and methods targeting coronaviruses |
WO2021205408A1 (en) * | 2020-04-10 | 2021-10-14 | Igy Immune Technologies And Life Sciences Inc. | Igy immunoglobulins targeting coronavirus, methods of preparing same, and methods of using same |
EP4136459A1 (de) | 2020-04-13 | 2023-02-22 | Abbott Laboratories | Verfahren, komplexe und kits zum nachweis oder zur bestimmung einer menge eines ss-coronavirus-antikörpers in einer probe |
WO2021232041A1 (en) * | 2020-05-09 | 2021-11-18 | Baylor College Of Medicine | N-acetylcysteine and glycine for treatment of covid-19 and post covid-19 symptoms |
JP2023524860A (ja) | 2020-05-11 | 2023-06-13 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | SARS-CoV-2ワクチン |
GB202007312D0 (en) * | 2020-05-18 | 2020-07-01 | Synthetic Vac Ltd | Mimotope peptides of the spike protein from the sars-cov-2 virus |
JP2023530274A (ja) * | 2020-06-12 | 2023-07-14 | ヴィア・バイオテクノロジー・インコーポレイテッド | SARS-CoV-2感染の抗体療法 |
KR20230035350A (ko) | 2020-07-06 | 2023-03-13 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | SARS-CoV-2를 표적으로 하는 항원 결합 분자 |
CA3187008A1 (en) * | 2020-07-27 | 2022-02-03 | Paul R. Hinton | Multimeric coronavirus binding molecules and uses thereof |
AU2021332340A1 (en) | 2020-08-26 | 2023-10-05 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
WO2022054068A1 (en) * | 2020-09-14 | 2022-03-17 | Ramot At Tel-Aviv University Ltd. | Antibodies for the prevention, treatment and detection of coronavirus infection |
EP3970798A1 (de) * | 2020-09-18 | 2022-03-23 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Sars-cov-2-nanokörper |
CN116390945A (zh) * | 2020-09-24 | 2023-07-04 | 博德研究所 | 无细胞抗体工程化平台和针对SARS-CoV-2的中和抗体 |
JP2023549677A (ja) * | 2020-11-06 | 2023-11-29 | チョ ファーマ インコーポレイテッド | 抗原およびその糖鎖操作抗体を含む免疫組成物 |
WO2022147147A1 (en) | 2020-12-30 | 2022-07-07 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
EP4370681A1 (de) * | 2021-07-16 | 2024-05-22 | Joint Stock Company "Biocad" | Auf influenzavirus basierendes isoliertes rekombinantes virus |
CN113908264B (zh) * | 2021-10-21 | 2023-06-23 | 中国人民解放军空军军医大学 | 基于噬菌体载体的新型冠状病毒疫苗及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL9101953A (nl) | 1991-11-21 | 1993-06-16 | Seed Capital Investments | Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen. |
US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
ES2190543T3 (es) | 1996-10-08 | 2003-08-01 | Bisys B V U | Procedimientos y sistemas que permiten seleccionar peptidos y proteinas que tienen una afinidad especifica respecto a un blanco. |
JP4210036B2 (ja) | 1999-04-15 | 2009-01-14 | クルセル ホランド ベー ヴェー | ヒト細胞における組み換え蛋白質の生産 |
AU2002345421B2 (en) | 2001-06-15 | 2006-11-16 | Crucell Holland B.V. | Chimaeric phages |
FR2828405B1 (fr) | 2001-08-09 | 2005-06-24 | Virbac Sa | Vaccin anti-coronavirus |
WO2004111081A2 (en) | 2003-06-13 | 2004-12-23 | Crucell Holland B.V. | Antigenic peptides of sars coronavirus and uses thereof |
WO2005012337A2 (en) | 2003-07-15 | 2005-02-10 | Crucell Holland B.V. | Antigenic peptides of sars coronavirus and uses thereof |
EP1646645A1 (de) | 2003-07-21 | 2006-04-19 | Crucell Holland B.V. | Antigene peptide des sars-coronavirus und anwendungen davon |
AU2004260884B2 (en) | 2003-07-22 | 2009-11-19 | Crucell Holland B.V. | Binding molecules against SARS-coronavirus and uses thereof |
US7396914B2 (en) | 2003-08-04 | 2008-07-08 | University Of Massachusetts | SARS nucleic acids, proteins, antibodies, and uses thereof |
CN1914226B (zh) * | 2003-11-25 | 2012-02-01 | 达纳-法伯癌症研究院有限公司 | SARS-CoV抗体及其使用方法 |
-
2005
- 2005-11-10 SG SG201000925-6A patent/SG159542A1/en unknown
- 2005-11-10 AU AU2005303758A patent/AU2005303758B2/en not_active Ceased
- 2005-11-10 EP EP05817101A patent/EP1812067B1/de active Active
- 2005-11-10 NZ NZ553701A patent/NZ553701A/xx not_active IP Right Cessation
- 2005-11-10 WO PCT/EP2005/055876 patent/WO2006051091A1/en active Application Filing
- 2005-11-10 CA CA2582057A patent/CA2582057C/en not_active Expired - Fee Related
- 2005-11-10 KR KR1020077009194A patent/KR101255861B1/ko not_active IP Right Cessation
- 2005-11-10 US US11/667,640 patent/US8106170B2/en not_active Expired - Fee Related
- 2005-11-10 AT AT05817101T patent/ATE550037T1/de active
Also Published As
Publication number | Publication date |
---|---|
US8106170B2 (en) | 2012-01-31 |
NZ553701A (en) | 2009-12-24 |
WO2006051091A1 (en) | 2006-05-18 |
CA2582057A1 (en) | 2006-05-18 |
EP1812067A1 (de) | 2007-08-01 |
AU2005303758A1 (en) | 2006-05-18 |
ATE550037T1 (de) | 2012-04-15 |
US20080014204A1 (en) | 2008-01-17 |
CA2582057C (en) | 2015-08-11 |
AU2005303758B2 (en) | 2011-04-28 |
EP1812067B1 (de) | 2012-03-21 |
KR101255861B1 (ko) | 2013-04-17 |
KR20070083768A (ko) | 2007-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG159542A1 (en) | Compositions against sars-coronavirus and uses thereof | |
ATE449097T1 (de) | Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer | |
WO2008057208A3 (en) | Hcv ns3 protease inhibitors | |
WO2008051514A3 (en) | Hcv ns3 protease inhibitors | |
WO2008051475A3 (en) | Hcv ns3 protease inhibitors | |
MX2009004556A (es) | Inhibidores de la proteasa ns3 del hcv. | |
WO2007092622A3 (en) | Compositions and methods for treating bone | |
WO2008051477A3 (en) | Hcv ns3 protease inhibitors | |
MY142240A (en) | Hcv ns3 protease inhibitors | |
WO2008127364A3 (en) | Antiviral compounds and use thereof | |
WO2007133865A3 (en) | Hcv/hiv inhibitors an their uses | |
WO2008115281A3 (en) | Compounds for treating viral infections | |
WO2007109105A3 (en) | Flavivirus inhibition by sultams and related compounds | |
WO2009152356A3 (en) | Compounds and compositions useful for the treatment of malaria | |
NO20084637L (no) | Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer | |
WO2006113919A3 (en) | Aryl alkyl acid derivatives for and use thereof | |
EA201001275A1 (ru) | Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с | |
NO20084645L (no) | Cyklopropyl kondenserte indolobenzazepin HCV NS5B inhibitorer | |
EA200801025A1 (ru) | Композиция и синтез новых реагентов для ингибирования репликации вич | |
WO2009156462A3 (en) | Organic compounds | |
MX2011006631A (es) | Inhibidores de proteasa ns3 del virus hcv. | |
TW200726471A (en) | Heteroaryl derivatives for treating viruses | |
EA200800889A1 (ru) | Гексагидроциклооктилпиразольные каннабиноидные модуляторы | |
WO2008034142A3 (en) | Synthesis, methods of using, and compositions of cycloalkylmethylamines | |
WO2009029384A3 (en) | Compounds for the treatment of hepatitis c |